A new meta-analysis examines the diagnostic benefit of this emerging complementary modality.
In a recently published systematic review and meta-analysis involving 60 studies and over 10,600 patients, researchers found that contrast-enhanced mammography (CEM) provided high sensitivity and specificity in diagnosing breast cancer.
According to the study, published in Radiology, the use of CEM with low-energy and recombined images demonstrated slightly higher sensitivity (95 percent) than the use of recombined images alone (94 percent) and 10 percent higher specificity (81 percent vs. 71 percent).
The study authors noted that a potential preference to employ CEM as opposed to contrast-enhanced MRI may stem “from its ability to correlate low-energy mammographic findings with enhancement.” They indicated this could be beneficial when it comes to assessing suspicious findings detected with mammography and supplemental breast cancer screening for patients with dense breasts. In subgroup analyses, CEM had a 95 percent pooled sensitivity and a 78 percent pooled specificity in the assessment of patients with dense breasts, and a 92 percent pooled sensitivity and an 84 percent pooled specificity in studies looking at mammography-detected suspicious findings.
Another benefit of CEM may be the screening of women who have undergone thoracic radiation therapy, according to lead author Andrea Cozzi, M.D., who is affiliated with the Department of Biomedical Sciences at Universita degli Studi di Milano in Milan, Italy, and colleagues. The study authors noted that these women have a higher risk of ductal carcinoma in situ with low neoangiogenesis, a finding that may be missed on CE-MRI but could be detected through the presence of calcifications on CEM.
“Interest in CEM stems from its potential to achieve the high sensitivity of a modality like breast MRI but without the associated limitations of MRI-limited accessibility and high cost,” wrote Manisha Bahl, M.D., M.P.H., a radiologist at Massachusetts General Hospital and Harvard Medical School, in an accompanying editorial.
While CEM does not have a specific Food and Drug Administration (FDA)-approved indication for breast cancer screening, Dr. Bahl wrote that large multicenter trials are currently underway to assess the screening capabilities of CEM.
Dr. Cozzi and colleagues conceded limitations of the study, including high heterogeneity, the small number of multicenter studies in their meta-analysis and a lack of randomized studies.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.